Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immune stimulating complexes as mucosal vaccines

R E Smith1, A M Donachie, A M Mowat

  • 1Department of Immunology, University of Glasgow, Western Infirmary, Scotland.

Immunology and Cell Biology
|July 31, 1998
PubMed
Summary

Lipophilic immune-stimulating complexes (ISCOMs) deliver antigens orally, inducing robust systemic and local immune responses. These novel mucosal vaccine vectors show promise for future vaccine development.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Colonic tolerance develops in the iliac lymph nodes and can be established independent of CD103(+) dendritic cells.

Mucosal immunology·2015
Same author

The lymph nodes draining the small intestine and colon are anatomically separate and immunologically distinct.

Mucosal immunology·2015
Same author

The regulation of immune responses to dietary protein antigens.

Immunology today·2014
Same author

Contrasuppressor cells in mucosal immunity.

Immunology today·2014
Same author

CCR2(+)CD103(-) intestinal dendritic cells develop from DC-committed precursors and induce interleukin-17 production by T cells.

Mucosal immunology·2014
Same author

Lymph-borne CD8α+ dendritic cells are uniquely able to cross-prime CD8+ T cells with antigen acquired from intestinal epithelial cells.

Mucosal immunology·2014

Area of Science:

  • Immunology
  • Vaccinology
  • Biotechnology

Background:

  • Developing non-living adjuvant vectors for oral vaccines is crucial for eliciting comprehensive immune responses.
  • Current vaccine vectors have limitations in achieving both local and systemic immunity.
  • Saponin adjuvants like Quil A are potent immune stimulators.

Purpose of the Study:

  • To evaluate lipophilic immune-stimulating complexes (ISCOMs) containing Quil A as a mucosal vaccine vector.
  • To assess the range of immune responses induced by orally administered ISCOMs with a model antigen.
  • To investigate the mechanisms underlying the adjuvant properties of ISCOMs.

Main Methods:

  • Oral administration of ISCOMs containing ovalbumin (OVA) to model systems.
  • Analysis of systemic immune responses, including T cell activity and antibody production.
  • Assessment of local intestinal immune responses, such as secretory IgA.
  • Investigation of inflammatory mediators, including interleukin-12.

Main Results:

  • Orally administered ISCOMs induced broad systemic immunity: Th1/Th2 CD4+ T cell activity, IgG antibodies, and cytotoxic T cell responses.
  • Local intestinal immunity was stimulated, with secretory IgA production and T cell priming in lymphoid tissues.
  • Interleukin-12, produced by dendritic cells/macrophages, was identified as a key inflammatory mediator.
  • ISCOMs demonstrated effective antigen delivery with the pro-inflammatory properties of Quil A.

Conclusions:

  • Lipophilic ISCOMs are effective non-living mucosal vaccine vectors for oral antigen delivery.
  • ISCOMs elicit diverse systemic and local immune responses, distinct from other vectors.
  • The combination of antigen delivery and Quil A's properties drives mucosal adjuvant effects, with IL-12 playing a central role.

Related Experiment Videos